CN104758936A - Synthetic small-molecular compound capable of transporting bioactive substances and application thereof - Google Patents
Synthetic small-molecular compound capable of transporting bioactive substances and application thereof Download PDFInfo
- Publication number
- CN104758936A CN104758936A CN201510105104.3A CN201510105104A CN104758936A CN 104758936 A CN104758936 A CN 104758936A CN 201510105104 A CN201510105104 A CN 201510105104A CN 104758936 A CN104758936 A CN 104758936A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- synthesized micromolecule
- bioactivator
- micromolecule compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 19
- 239000000126 substance Substances 0.000 title claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002532 enzyme inhibitor Substances 0.000 claims description 5
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- -1 monoclonal antibody Proteins 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 claims description 4
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 4
- 108010068072 salmon calcitonin Proteins 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 101001011741 Bos taurus Insulin Proteins 0.000 claims description 2
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229940045644 human calcitonin Drugs 0.000 claims description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 2
- 229950004152 insulin human Drugs 0.000 claims description 2
- 239000003055 low molecular weight heparin Substances 0.000 claims description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000012744 reinforcing agent Substances 0.000 claims description 2
- 229960004532 somatropin Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000032895 transmembrane transport Effects 0.000 description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000168254 Siro Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A synthetic small-molecular compound capable of transporting bioactive substances and an application thereof, wherein the synthetic small-molecular compound or any one pharmaceutically acceptable salt thereof has a general formula as follows, wherein A, B and C are substituent groups including, but not limit to the following group: a hydrogen atom, a halogen atom, a C1-C4 saturated alkyl group, a C3-C6 naphthenic alkyl group, an O-C1-C4 saturated alkyl group, an O-C3-C6 naphthenic alkyl group, OH, NH2, CN, NO2, CF3, NHCO(C1-C4 saturated alkyl group, C3-C6 naphthenic alkyl group, C6-C10 aromatic ring or C5-C9 hetero-aromatic ring), or OCF3; the D is O, NH or CH2; and the E is a carboxyl group (COOH), CONHOH, a tetrazole group, OH or a sulfonic group. The n is an integer including 0, 1, 2, 3, 4, 5 and 6.
Description
Technical field
The present invention relates to one and bioactive substance (comprising chemosynthesis active substance) can be delivered to micromolecular compound in organism and application thereof.
Background technology
There is bioactive material be transported in organism by several routes, but which kind of method can reach objective condition when conveying object is often limited by conveying actually.
The clinical conventional route of administration that great majority have bioactive material (as calcitonin, interferon, insulin, special mucopolysaccharide, heparin, hyparinoids from animal organs etc.) is injection solution agent and lyophilized injectable powder, route of administration is more single, and frequent drug administration, patient's poor compliance.At present, the greatest problem of this type of material oral administration be the physics of body, chemistry and biology barriers affect its send.Such as, protein drug cannot adopt oral administration, this is mainly because this kind of medicine is before being rapidly absorbed into blood circulation through digestive tract, often by the hydrolysis of strong gastric acid or degrade by the multiple digestive enzyme of gastrointestinal, thus lose biological activity.Nearly all natural polypeptides, protein, polysaccharide, phospholipid and lipoid etc. are all degraded into junior unit and by intestinal absorption in the intestines and stomach.
Therefore, just must consider these objective condition when design has bioactive molecule oral administration route, the method using some feasible is to reduce the degraded of this kind of medicine in the intestines and stomach.
Conventional method uses penetrating agent, as surfactant, fatty acid or cholate, increases the permeability of rete malpighii and epithelium layer, expand intercellular substance.The most frequently used oral absorption promoter is cholate and fatty acid, and also someone uses sodium salicylate.The disadvantage of such material be non-selectivity act on lipid sur and all small intestine contents compositions may be made to comprise various toxin and bio-pathogen enters blood, also have the toxicity such as potential cellular membrane lysis and local inflammation; Nearly all polypeptide drugs and mucosa transmission all need penetrating agent, its broad categories, and existing problems how to reduce stimulation and whether life-time service affects epithelial integrity, causes coup injury to mucosa, therefore its application is clinically restricted.
Application protease inhibitor can stop gastro-intestinal digestion enzyme to the destruction of insulin etc., conventional enzyme inhibitor has sodium glycocholate, camostat mesilate, bacitracin, aprotinin, Semen sojae atricolor pancreatin inhibitor etc., front 3 kinds of effects are better, the absorption of the large intestinal segment that major effect protease is concentrated.But enzyme inhibitor, while significantly improving protein and peptide drugs oral administration bioavailability, also can bring a lot of untoward reaction.Even if ignore its Systemic reaction, it also can have an impact to digesting and assimilating of Intra-intestinal nutrition support albumen, produces feedback regulation, thus stimulate enzyme secretion to the inhibitory action of gastrointestinal proteases, and long-term treatment also can cause spleen hypertrophy and hypertrophy; Enzyme inhibitor is also easily diluted in intestinal, and therefore use amount just must strengthen, and the excessive toxic reaction causing various system of use amount.
By adjusting close-connected permeability, can improve the percent of pass of macromolecular drug at intercellular substance, result shows, the compact siro spinning technology although a lot of material can relax, significantly improves the permeability of medicine at intercellular substance, but occur safety issue simultaneously.Compact siro spinning technology is once be opened, and except medicine can pass through, some albumen poisonous or harmful in digestive tract also can pass through.Because a lot of biological medicament is all for chronic disease treatment, Long-term absorption deleterious protein is the problem that this approach must be paid close attention to.
The physicochemical property of macromolecular drug being modified, by preparing the method for prodrug or analog, protease or digestive tract other enzymes interior can be avoided the degraded of polypeptide protein class medicine.Such as; medicine is combined with form covalently or non-covalently with a fat-soluble compound by lipophilization, increases the fat-soluble of polypeptide protein class medicine, or combines with Polyethylene Glycol (PEG); the water solublity of medicine can be increased, medicine can be protected from the degraded of digestive system protease.The range of application of polypeptide drugs has been widened in being applied in of prodrug to a great extent, but dressing agent presents multiple polymerization, and selectivity is not high enough, and the medicine Mr distribution after modification is wide, activity is low, stability is sometimes not ideal enough becomes outstanding problem; In addition its structural complexity and the effective synthesis technique of shortage, are all bottlenecks.
Utilize transhipment-carrier molecule, it is combined with polypeptide protein medicine, thus endogenic cell-movement system identified in digested road, the oral administration biaavailability of polypeptide protein class medicine can be improved, this transhipment principle is relevant with the endocytosis of the carrier mediated and receptor modulators on cell membrane, the part that mediation or endocytosis are connected with macromolecular drug can be identified specifically, thus reach the transmembrane transport to macromolecular drug.Such as, medicine is combined with certain dipeptides, this two Toplink by the peptide-Nei on cell membrane flow carrier identify mediation, thus the macromolecular transmembrane transport of realize target, the oral administration biaavailability of macromolecular drug is improved.Outer row's carrier, such as P glycoprotein, can have a strong impact on some macromolecular drugs, as the oral absorption of polypeptide, therefore, adopts P glycoprotein inhibitors, may increase the oral absorption to P glycoprotein substrate to a certain extent.But, generally speaking, the identification mediation of cell membrane carrier can only realize the transmembrane transport of the relatively little molecule of number molecular weight.On the contrary, the cellular endocytosis machinery of receptor modulators is not but substantially by the impact of molecular size.
Cell permeable polypeptide (CPP) may be by carrying out heterozygosis with target substance, thus helps micromolecule, macromole, liposome and nanoparticle etc., through cell or tissue.Have research to think, the mechanism of action of CPP may be lipid bilayer Rotating fields by direct interference cell membrane or endocytosis, by by the substance delivery that transmits in Cytoplasm.But up to the present, also lack Data support in enough bodies to the research of CPP delivering method, they are also indefinite with effect to the delivery mechanism of medicine over the course for the treatment of.
Particulate carrier delivery system can protect the macromolecular drug of easy inactivation in the violent environment of digestive tract, from metabolism and the degraded of enzyme system.When not adding penetrating agent, some particulate carrier can absorb by epithelial cell, or by lymphoid tissue PeyerShi knot (Peyer ' s Patch) absorb.To develop based on hydrogel, nanoparticle, microsphere at present, and the high molecular particle drug-loading system of lipid (such as microemulsion, liposome and solid lipid nanoparticle) etc., and for the oral delivery of macromolecular drug.But in these particulate carrier delivery systems, lipid drug delivery system, for large hydrophilic molecular medicine, can not reach higher envelop rate.In addition, their less stable in digestive tract.Common liposome and microemulsion cannot meet the oral delivery of large hydrophilic molecular medicine substantially.
Although some follow-on lipid carriers, such as through the fusogenic lipid plastid of viral glycoprotein parcel, or the liposome of adhesiveness macromolecular material coating, although they significantly improve the absorption of large hydrophilic molecular medicine in small intestinal, but generally speaking, solid particle, than lipid carrier, has more advantage in the oral delivery of macromolecular drug.
Summary of the invention
The technical problem solved: the object of the invention is to overcome the above-mentioned defect that prior art exists, provides a kind of and bioactive substance effectively can be delivered to micromolecular compound in organism and application thereof.
Technical scheme: the micromolecular compound of the present invention is micromolecular compound or the pharmaceutically useful salt of its any one with following general formula:
In described general formula:
A, B and C are substituent group; Can be but be not limited to hydrogen, halogen, C
1-C
4saturated alkyl, C
3-C
6cycloalkyl, O-C
1-C
4saturated alkyl, O-C
3-C
6cycloalkyl, OH, NH
2,cN, NO
2, CF
3, NHCO (C
1-C
4saturated alkyl, C
3-C
6cycloalkyl, C
6-C
10aromatic ring or C
5-C
9hetero-aromatic ring) or OCF
3;
D is O, NH or CH
2;
E is carboxylic acid group (COOH) ,-CONHOH, tetrazolium, OH ,-SO
3h.
N is integer 0,1,2,3,4,5,6.
Wherein, preferred compound is as shown in the table:
Apply the synthesized micromolecule compound of described energy conveying bioactivator, the preparation containing one or more bioactive substances can be made.
The described preparation containing bioactive substance is the mixture under a specific acid basicity, if its acid-base value characterizes with pH value, then its value can be but is not limited to 2,3,4,5,6,7 or 8.
Described preparation can be liquid, suspension containing solid or solid.
Described have bioactive material and can be protein, polypeptide, polysaccharide, vitamin, rare metal or micromolecule medicine, and the mol ratio of described micromolecular compound and bioactive substance is: 1:0.01-1000.
The preferred molar ratio of described micromolecular compound and bioactive substance is: 1:0.1,1:0.5,1:1,1:5,1:10,1:20,1:50,1:100,1:200,1:500.
Described to have bioactive material be selected from least one in following material: enzyme inhibitor, protease inhibitor, growth hormone, human growth hormone, recombinant human somatropin, heparin, unfraction heparin, low molecular weight heparin, calcitonin, salmon calcitonin see calcimar, eel calcitonin, human calcitonin, insulin, Iletin II (Lilly), bovine insulin, insulin human, recombinant human insulin, prostaglandin, monoclonal antibody, antigen, PYY
3-36, antiinflammatory, antioxidant, antibacterial, antimicrobial, vitamin, and by poly ethyldiol modified various derivants.
Described preparation, can be a kind of unit dosage form, at least one containing in lower material: reinforcing agent, chelating agent, plasticizer, buffer agent, surfactant, acid-base modifier.
Described unit dosage form can be lamellar, capsule, powder, liquid or the suspension containing solid.
If described unit dosage form contains suspension or the liquid of solid, then carrier can be but be not limited to water, ethylene glycol, glycerol.
Beneficial effect: the micromolecular compound of the present invention effectively can be delivered in organism by the approach such as oral cavity, colon by having bioactive material, realize organism administration, namely the stability of medicine can be improved, improve medicine absorbance in the gastrointestinal tract, biomacromolecule is prevented to be degraded very soon in vivo, guarantee that the content of this active substance in vivo exceedes the amount produced needed for biological agent, medicine orientation can also be sent to body target site, and reach slow release long-acting object by the degraded of biodegradable polymers; Oral administration is convenient simultaneously, good patient compliance.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described.
Embodiment 1: the preparation of compound
Method one: add EDC (1.0 equivalent) in dichloromethane (30 milliliters) solution being dissolved with chromone-3-formic acid derivates (1.0 equivalent), this solution stirred after 20 minutes at 0 DEG C, dichloromethane (10 milliliters) solution containing amine (1.0 equivalent) and triethylamine (2.0 equivalent) is added in solution, after interpolation, reaction mixture is warmed to room temperature gradually and at room temperature stirs 12 hours.
Solution is proceeded to separatory funnel, use 1 equivalent hydrochloric acid solution (2x 20 milliliters) respectively, water (2X 20 milliliters), saturated charcoal acid hydrogen sodium solution (2X 20 milliliters), saturated brine (40 milliliters) is washed. and with anhydrous magnesium sulfate drying, filter, vacuum concentration. subsequently, residue be dissolved in oxolane (30 milliliters) and add hydrogen-oxygen flower sodium solution (2 equivalent). this mixture at room temperature stirs 5 hours. after vacuum concentration, use 1.0N hcl acidifying. collect the solid formed with filtration under diminished pressure, obtain pure compound with ethanol/water recrystallization.
Compound 1-9 is synthesized by the suitable initiation material of said method.
Embodiment 1: Oral Administration in Rats heparin administration
Heparin is a kind of by glucamine, the mucopolysaccharide sulfuric acid ester that L-idose aldehyde glycosides, N-Acetyl-D-glucosamine and D-Glucose aldehydic acid alternately form.Have anticoagulation, suppress platelet, increase the effects such as the permeability of blood vessel wall, controllable angiogenesis, Adjust-blood lipid, and multiple links that can act on complement system, to suppress system excessive activation.Related to this, heparin also has antiinflammatory, antianaphylactic effect.
Be dissolved in the aqueous solution of propylene glycol of 25% to 1,3,5,8,13,16,26 in each compound listed by claim 2 according to the compound dosage in following table and corresponding heparin amount, and by the sodium hydrate aqueous solution adjust ph to 8.0 of monovalent, make it to become even oral administration mixture with ultrasonic wave concussion subsequently.
It is the male rat fasting 24 hours of 200-250 gram by weight, within 15 minutes, inject ketamine (44mg/kg) to rat muscle before administration, the latex tubing being 5mm by the diameter that connects syringe is subsequently inserted in stomach through rat oral cavity, and oral administration mixture (1ml) is sent in the stomach of rat by syringe through latex tubing; Be interval in rat tails at different time subsequently and get blood.The activity of Oral Heparin was expressed by the part activated thrombin time (APTT).Method of testing according to Henry, J.B. at " method of room carries out clinical diagnosis and management by experiment " (Clinical Diagnosis and Management by Laboratory Methods; Philadelphia, PA; W.B.Saunders 1979) described in method carry out.
Table 1 Oral Administration in Rats heparin administration data
+ represent APTT<30s
++ represent 30<APTT<80s
+++ represent 80<APTT<100s
++++represent APTT>140s
Embodiment 2: Oral Administration in Rats insulin administration
Prepare oral insulin drug-delivery preparation: by compound dissolution in table 2 in the sodium hydrate aqueous solution of equivalent, insulin is then dissolved in appropriate water, these two kinds of solution mixing is also fully stirred subsequently and forms homogeneous phase solution with for subsequent use.
It is the male rat fasting 24 hours of 200-250 gram by weight, anaesthetize within 15 minutes, to before administration rat through lumbar injection pentobarbital sodium 40mg/kg, after anesthesia, animal is fixed on operation plate, the latex tubing being 5mm by the diameter that connects syringe is subsequently inserted in stomach through rat oral cavity, and oral administration mixture (2mL) is sent in the stomach of rat through latex tubing by syringe.Be interval in rat tail point at different time subsequently and get blood, after blood coagulation centrifugal (3000r/min, 15min), get serum, by blood sugar detection requirement, measure blood glucose and reduce level.
Table 2 Oral Administration in Rats insulin data
+ represent blood glucose reduce be less than 5
++ represent blood glucose reduction and be greater than 5 but be less than 10
+++ represent blood glucose and reduce and be greater than 10 and be less than 20
The reduction of ++++represent blood glucose is greater than 20 and is less than 35%.
Claims (10)
1. the synthesized micromolecule compound of energy conveying bioactivator, it is characterized in that, it is micromolecular compound or the pharmaceutically useful salt of its any one with following general formula:
I
In described general formula:
A, B and C are substituent group; A, B, C comprise hydrogen, halogen, C
1-C
4saturated alkyl, C
3-C
6cycloalkyl, O-C
1-C
4saturated alkyl, O-C
3-C
6cycloalkyl, OH, NH
2,cN, NO
2, CF
3, NHCO (C
1-C
4saturated alkyl, C
3-C
6cycloalkyl, C
6-C
10aromatic ring or C
5-C
9hetero-aromatic ring) or OCF
3;
D is O, NH, or CH
2;
E is carboxylic acid group (COOH) ,-CONHOH, tetrazolium, OH ,-SO
3h;
N is integer 0,1,2,3,4,5,6.
2. the synthesized micromolecule compound of energy conveying bioactivator according to claim 1, is characterized in that, is following one or more listed micromolecular compounds:
（1）
；
（2）
；
（3）
；
（4）
；
（5）
；
（6）
；
（7）
；
（8）
；
（9）
。
3. require according to claims the preparation that the synthesized micromolecule compound of the energy conveying bioactivator described in 1 or 2 is made, it is characterized in that, described preparation contains one or more and has bioactive material.
4. according to claim 3 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, the pH value of described preparation is 2,3,4,5,6,7 or 8.
5. according to claim 3 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, described preparation is liquid, suspension containing solid or solid.
6. according to claim 3 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, described to have bioactive material be protein, polypeptide, polysaccharide, vitamin, rare metal or micromolecule medicine, and the mol ratio of described micromolecular compound and bioactive substance is: 1:0.01-1000.
7. according to claim 6 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, the mol ratio of described micromolecular compound and bioactive substance is: 1:0.1,1:0.5,1:1,1:5,1:10,1:20,1:50,1:100,1:200,1:500.
8. according to claim 3 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, described to have bioactive material be selected from least one in following material: enzyme inhibitor, protease inhibitor, growth hormone, human growth hormone, recombinant human somatropin, heparin, unfraction heparin, low molecular weight heparin, calcitonin, salmon calcitonin see calcimar, eel calcitonin, human calcitonin, insulin, Iletin II (Lilly), bovine insulin, insulin human, recombinant human insulin, prostaglandin, monoclonal antibody, antigen, PYY
3-36, antiinflammatory, antioxidant, antibacterial, antimicrobial, vitamin, and by poly ethyldiol modified various derivants.
9. according to claim 3 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, for a kind of unit dosage form, at least one containing in lower material: reinforcing agent, chelating agent, plasticizer, buffer agent, surfactant, acid-base modifier.
10. according to claim 9 can the preparation made of the synthesized micromolecule compound of conveying bioactivator, it is characterized in that, unit dosage form is lamellar, capsule, powder, liquid or the suspension containing solid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510105104.3A CN104758936A (en) | 2015-03-11 | 2015-03-11 | Synthetic small-molecular compound capable of transporting bioactive substances and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510105104.3A CN104758936A (en) | 2015-03-11 | 2015-03-11 | Synthetic small-molecular compound capable of transporting bioactive substances and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104758936A true CN104758936A (en) | 2015-07-08 |
Family
ID=53641246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510105104.3A Pending CN104758936A (en) | 2015-03-11 | 2015-03-11 | Synthetic small-molecular compound capable of transporting bioactive substances and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758936A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034632A1 (en) * | 1997-02-07 | 1998-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CN1190893A (en) * | 1995-03-31 | 1998-08-19 | 艾米斯菲尔技术有限公司 | Compound and compositions for delivering active agents |
-
2015
- 2015-03-11 CN CN201510105104.3A patent/CN104758936A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1190893A (en) * | 1995-03-31 | 1998-08-19 | 艾米斯菲尔技术有限公司 | Compound and compositions for delivering active agents |
| WO1998034632A1 (en) * | 1997-02-07 | 1998-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules | |
| US5744166A (en) | Drug delivery compositions | |
| ES2200306T3 (en) | KITOSAN A GELATINE MICRO-PARTICLES. | |
| EP2308473A1 (en) | Pharmaceutical composition containing surface-coated microparticles | |
| CN105164143B (en) | Cholesterol vesicles for introducing molecules into chylomicrons | |
| JP4489356B2 (en) | Penetration enhancer | |
| Soudry-Kochavi et al. | Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach | |
| TWI732773B (en) | Compositions and methods for nanoparticle lyophile forms | |
| US20070134332A1 (en) | Polymer particles for delivery of macromolecules and methods of use | |
| JP6438406B2 (en) | Compositions and methods for delivering hydrophobic bioactive agents | |
| ES2848210T3 (en) | Nanoencapsulation of hydrophilic active compounds | |
| CN102813937A (en) | Hydrophobic drug containing polyelectrolyte complex, its preparation method and application thereof | |
| Li et al. | Reduction breakable cholesteryl pullulan nanoparticles for targeted hepatocellular carcinoma chemotherapy | |
| JP2016510001A (en) | Targeted buccal delivery containing cisplatin filled chitosan nanoparticles | |
| ES2761227T3 (en) | An extended-release composition comprising a microparticle somatostatin derivative | |
| CN110662550A (en) | Oral administration of physiologically active substances | |
| CN109966507A (en) | A tumor-targeted pH- and redox-responsive macromolecular nanoprodrug and its preparation method and application | |
| WO2005079749A2 (en) | Chitosan containing solution | |
| Peng et al. | Challenges and opportunities in delivering oral peptides and proteins | |
| CN106883404B (en) | Polyethylene glycol vitamin E succinate derivative and its preparation method and application | |
| Elmorshedy et al. | Engineered microencapsulated lactoferrin nanoconjugates for oral targeted treatment of colon cancer | |
| Zainuddin et al. | Chitosan-based oral drug delivery system for peptide, protein and vaccine delivery | |
| CN103110567B (en) | The Preparation method and use of the administration nano-drug administration system of a kind of year tanshinone ⅡA | |
| Werle et al. | Oral protein delivery: a patent review of academic and industrial approaches | |
| CN101555212B (en) | Synthesized micromolecule compound capable of conveying bioactivator and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150708 |
|
| RJ01 | Rejection of invention patent application after publication |